Stockreport

CARsgen's CAR T MM therapy shows early signs of efficacy in Phase I trial [Yahoo! Finance]

Pfizer, Inc.  (PFE) 
Last pfizer, inc. earnings: 4/28 06:45 am Check Earnings Report
PDF CT071 is CAR T cell drug that acts by binding to cells expressing GPRC5D. It was developed using CARsgen's CARcelerate platform for the treatment of patients with RRMM [Read more]